Daniel DeAngelo
Impact in
- Hematology top 0.01%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- Genetics top 0.05%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
Papers in
- Hematology 291
- Acute Myeloid Leukemia Research 179
- Chronic Myeloid Leukemia Treatments 132
- Genetics 142
- Chronic Lymphocytic Leukemia Research 89
- Myeloproliferative Neoplasms: Diagnosis and Treatment 46
- Co-authors
- Richard Maury Stone (124 shared papers)Martha Wadleigh (58 shared papers)Ilene A Galinsky (39 shared papers)Anjali S. Advani (35 shared papers)Wendy Stock (42 shared papers)Donna S Neuberg (44 shared papers)Hagop Kantarjian (33 shared papers)Robert J. Soiffer (22 shared papers)
- Journals
- Blood (158 papers)Leukemia (25 papers)Blood Advances (24 papers)American Journal of Hematology (21 papers)Leukemia Research (14 papers)
- Partner nations
- United StatesGermanyUnited Kingdom
In The Last Decade
Daniel DeAngelo
467 papers receiving 30.2k citations
Daniel DeAngelo's Hit Papers
Peers
Comparison fields: 5 of 145
- Hematology 15.7k
- Genetics 7.2k
- Oncology 6.7k
- Public Health, Environmental and Occupational Health 6.7k
- Rheumatology 3.2k
Countries citing papers authored by Daniel DeAngelo
This map shows the geographic impact of Daniel DeAngelo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel DeAngelo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel DeAngelo more than expected).
Fields of papers citing papers by Daniel DeAngelo
This network shows the impact of papers produced by Daniel DeAngelo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel DeAngelo. The network helps show where Daniel DeAngelo may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel DeAngelo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 488 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome Hit paper breakdown → | 2003 | 1347 |
| 2 | Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia Hit paper breakdown → | 2017 | 1212 |
| 3 | MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia Hit paper breakdown → | 2006 | 1197 |
| 4 | Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia Hit paper breakdown → | 2016 | 1115 |
| 5 | A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias Hit paper breakdown → | 2013 | 940 |
| 6 | Differentiation and reversal of malignant changes in colon cancer through PPARγ Hit paper breakdown → | 1998 | 893 |
| 7 | Acute myeloid leukemia ontogeny is defined by distinct somatic mutations Hit paper breakdown → | 2014 | 806 |
| 8 | Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission Hit paper breakdown → | 2009 | 728 |
| 9 | KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study Hit paper breakdown → | 2021 | 627 |
| 10 | Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia Hit paper breakdown → | 2013 | 608 |
| 11 | 2004 | 578 | |
| 12 | Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy Hit paper breakdown → | 2011 | 501 |
| 13 | Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial Hit paper breakdown → | 2018 | 454 |
| 14 | 2010 | 441 | |
| 15 | Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms Hit paper breakdown → | 2018 | 398 |
| 16 | Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure Hit paper breakdown → | 2019 | 365 |
| 17 | 2012 | 300 | |
| 18 | 2009 | 291 | |
| 19 | Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia Hit paper breakdown → | 2014 | 287 |
| 20 | Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study Hit paper breakdown → | 2019 | 280 |
About Daniel DeAngelo
Daniel DeAngelo is a scholar working on Hematology, Genetics, Public Health, Environmental and Occupational Health, Oncology and Rheumatology, having authored 488 papers that have together received 30.9k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (179 papers), Acute Lymphoblastic Leukemia research (146 papers), Chronic Myeloid Leukemia Treatments (132 papers), Chronic Lymphocytic Leukemia Research (89 papers), Eosinophilic Disorders and Syndromes (46 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (46 papers), CAR-T cell therapy research (45 papers) and Histone Deacetylase Inhibitors Research (35 papers). The work is most often cited by research in Hematology (15.7k citations), Genetics (7.2k citations), Oncology (6.7k citations), Public Health, Environmental and Occupational Health (6.7k citations) and Rheumatology (3.2k citations). Daniel DeAngelo has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Richard Maury Stone, Martha Wadleigh, Ilene A Galinsky, Anjali S. Advani, Wendy Stock, Donna S Neuberg, Hagop Kantarjian, Robert J. Soiffer, Erik R. Vandendries and Benjamin L. Ebert. Their work appears in journals such as Blood, Leukemia, Blood Advances, American Journal of Hematology and Leukemia Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.